CLECL1P: A Protein Involved in Neural Circuits and Drug Targets

Target Name: CLECL1P

NCBI ID: G160365

CLECL1P

CLECL1P: A Protein Involved in Neural Circuits and Drug Targets

CLECL1P (CLECL1-related protein 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidney. It is a member of the clecl gene family, which encodes a family of proteins that play a critical role in various cellular processes, including cell signaling, DNA replication, and cellular adhesion.

One of the functions of CLECL1P is to regulate the activity of the neurotransmitter GABA, which is a chemical that is involved in a wide range of physiological processes, including mood regulation, learning and memory, and neuroprotection. GABA is known for its ability to inhibit the activity of other neurons, which is important for the proper functioning of the nervous system.

In recent years, the role of GABA in the regulation of neural circuits has received a lot of attention. Studies have shown that changes in GABA levels or the ability of neurons to regulate GABA levels can have a significant impact on the function of the nervous system . For example, evidence has suggested that increased levels of GABA in the brain may be associated with reduced activity in regions of the brain that are involved in decision-making and emotion, while decreased GABA levels in the brain have been linked to increased activity in regions involved in fear and anxiety.

CLECL1P is also known for its role in regulating the activity of other signaling molecules, including neurotransmitters that are involved in pain perception and neuroprotection. For example, studies have shown that clecl1p can interact with the neurotransmitter N-methyl-D-aspartate (NMDA) , which is involved in pain signaling. This interaction may be important for the regulation of pain sensitivity and the development of chronic pain.

In addition to its role in regulating neurotransmitter signaling, CLECL1P is also involved in the regulation of cellular processes that are critical for the survival and function of neurons. For example, studies have shown that clecl1p can interact with the protein p53, which is a well -known tumor suppressor protein. This interaction may be important for the regulation of cell growth and the ability of neurons to respond to environmental stimuli.

CLECL1P is also of interest as a potential drug target. Studies have shown that clecl1p can be targeted by small molecules, including inhibitors of the enzyme tyrosine kinase. This suggests that drugs that inhibit tyrosine kinase activity may be effective in reducing the activity of clecl1p and potentially treating a variety of neurological and psychiatric disorders.

In conclusion, CLECL1P is a protein that is expressed in various tissues throughout the body and is involved in a wide range of cellular processes that are critical for the survival and function of neurons. Its role in the regulation of neurotransmitter signaling, cellular processes, and the survival of neurons makes it an attractive target for the development of new drugs for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the functions of clecl1p and its potential as a drug target.

Protein Name: C-type Lectin Like 1, Pseudogene

Functions: May function in mediating immune cell-cell interactions. May act as a T-cell costimulatory molecule, enhancing anti-CD3-induced proliferation. May play a role in the interaction of dendritic cells with T-cells and the cells of the adaptive immune response

The "CLECL1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLECL1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets